| 1.67 -0.1 (-5.65%) | 11-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.25 | 1-year : | 2.62 |
| Resists | First : | 1.92 | Second : | 2.25 |
| Pivot price | 1.74 |
|||
| Supports | First : | 1.58 | Second : | 1.37 |
| MAs | MA(5) : | 1.74 |
MA(20) : | 1.73  |
| MA(100) : | 1.88 |
MA(250) : | 1.05 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 53.2 |
D(3) : | 56.9 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 3.24 | Low : | 0.27 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HYFT ] has closed above bottom band by 12.0%. Bollinger Bands are 76.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.8 - 1.81 | 1.81 - 1.81 |
| Low: | 1.62 - 1.63 | 1.63 - 1.64 |
| Close: | 1.65 - 1.67 | 1.67 - 1.68 |
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
Fri, 07 Nov 2025
MindWalk Holdings Enters Sales Agreement with JonesTrading - MSN
Tue, 21 Oct 2025
MindWalk Appoints R. Scott Areglado as Chief Financial Officer - citybiz
Fri, 17 Oct 2025
MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points (NASDAQ:HYFT) - Seeking Alpha
Tue, 23 Sep 2025
MindWalk Holdings Corp. (HYFT) Surges with 45% Revenue Growth and Strategic AI-Focused Rebrand - Yahoo Finance
Tue, 16 Sep 2025
MindWalk Holdings Corp (HYFT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Mon, 15 Sep 2025
MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 46 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 9 (%) |
| Held by Institutions | 8.8 (%) |
| Shares Short | 696 (K) |
| Shares Short P.Month | 861 (K) |
| EPS | -0.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.44 |
| Profit Margin | -115.9 % |
| Operating Margin | -131.6 % |
| Return on Assets (ttm) | -14.6 % |
| Return on Equity (ttm) | -112.4 % |
| Qtrly Rev. Growth | 27.7 % |
| Gross Profit (p.s.) | 0.3 |
| Sales Per Share | 0.54 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -2.79 |
| PEG Ratio | 0 |
| Price to Book value | 3.71 |
| Price to Sales | 3.05 |
| Price to Cash Flow | -8.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|